Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $2.9 million.

  • Angiodynamics' Share-based Compensation rose 1435.92% to $2.9 million in Q4 2025 from the same period last year, while for Nov 2025 it was $11.4 million, marking a year-over-year increase of 1131.73%. This contributed to the annual value of $9.8 million for FY2025, which is 718.97% down from last year.
  • According to the latest figures from Q4 2025, Angiodynamics' Share-based Compensation is $2.9 million, which was up 1435.92% from $4.5 million recorded in Q3 2025.
  • Angiodynamics' Share-based Compensation's 5-year high stood at $4.5 million during Q3 2025, with a 5-year trough of $1.6 million in Q2 2025.
  • For the 5-year period, Angiodynamics' Share-based Compensation averaged around $2.7 million, with its median value being $2.6 million (2024).
  • Its Share-based Compensation has fluctuated over the past 5 years, first crashed by 4397.01% in 2023, then surged by 4486.97% in 2024.
  • Quarter analysis of 5 years shows Angiodynamics' Share-based Compensation stood at $3.0 million in 2021, then grew by 11.37% to $3.4 million in 2022, then tumbled by 43.97% to $1.9 million in 2023, then skyrocketed by 34.68% to $2.5 million in 2024, then grew by 14.36% to $2.9 million in 2025.
  • Its Share-based Compensation stands at $2.9 million for Q4 2025, versus $4.5 million for Q3 2025 and $1.6 million for Q2 2025.